Generate a tailored SOP for Dr. Joel Chamberlain. Improve your application with a focused, well-structured draft.
Joel Chamberlain moved to the University of Washington in 2001 after completing his graduate training in Cell and Molecular Biology at the University of Michigan Medical School. His postdoctoral training was at the University of Washington, culminating in an authored manuscript in 'Science' detailing gene targeting using adeno-associated viral vectors for the development of therapies for bone diseases. He has developed a gene therapy research program aimed at treating dominantly inherited muscle disorders, particularly using RNA interference methods for common adult muscular dystrophies, including facioscapulohumeral dystrophy (FSHD) and myotonic dystrophy (DM). At the University of Washington, he investigates FSHD patient muscle biopsies and works on developing therapeutic tools to modulate the expression of genes responsible for these muscular dystrophies, striving to create safe and effective therapies for dominant genetic diseases.
Standard Graduate School requirements for University of Washington apply to most departments listed unless specified otherwise by the program.